



2-5-14, Shinyokohama, Kouhoku-ku,  
Yokohama, Kanagawa 222-0033 Japan

+81.45.478.0041 Phone  
+81.45.478.0043 Fax  
[www.medinet-inc.co.jp/english/index.html](http://www.medinet-inc.co.jp/english/index.html)

22 Firstfield Road, Suite 250  
Gaithersburg, MD 20878

301.944.1700 Phone  
301.944-1703 Fax  
[www.maxcyte.com](http://www.maxcyte.com)

*Contacts:*

**Medinet Co., Ltd.**  
Kiyoshi Yokokawa  
+81-45-478-0041

**MaxCyte, Inc.**  
Doug Doerfler  
301-944-1620

## **MEDINET AND MAXCYTE INITIATE COLLABORATION FOR NOVEL CANCER IMMUNO-CELL THERAPY**

*Amended August 22, 2006 from original release dated August 16, 2006:*

**Gaithersburg, MD and Yokohama, Japan – August 16, 2006** – MaxCyte, Inc. and Medinet Co., Ltd. announced the signing of a collaboration agreement, made on August 9, 2006. Under this Agreement MaxCyte will optimize its proprietary cell loading system for the development of Medinet’s novel cancer immuno-cell therapy and implementation in a closed-system manufacturing process at Medinet’s four cell processing centers in Japan. MaxCyte and Medinet have also agreed to key terms for a commercial license to MaxCyte’s cell loading system to support clinical studies and commercialization of Medinet’s immunotherapy service.

“We are developing a novel cancer immunotherapy approach using cells from the patient’s own immune system and believe that the MaxCyte system can be a key enabling technology in our manufacturing process,” said Yoshiji Kimura, Medinet’s CEO. “Immuno-cell therapy is a treatment method in which immune cells are taken from a patient and cultured and processed to enhance their activity, then re-administered to the patient. We believe this therapeutic shows great potential and we are excited to enter into this relationship with MaxCyte. We believe that MaxCyte’s technology can greatly contribute to Medinet’s continued success as a leader in immuno-cell therapy in Japan.”

“As one of the world’s leading cell therapy companies we are constantly working to enhance the efficacy of cancer immuno-therapies,” said Yoshiji Kimura, President and CEO of Medinet. “We believe MaxCyte, with its unparalleled cell transfection capabilities, can be a key partner in developing our novel approach to improving cell therapy. This new approach shows great potential and we are excited to enter into this relationship with MaxCyte. We expect that MaxCyte’s technology can greatly contribute to MediNet’s continued success as a leader in immuno-cell therapy in Japan.”

“We are very pleased to be collaborating with Medinet to enable their promising immuno-cell therapy program. Our technology has been shown to provide unparalleled efficiency, reproducibility, and scalability for cell therapy products and services such as Medinet’s, providing reduced risk and enhanced efficacy, and thus accelerating drug development and commercial use,” said Douglas Doerfler, President and CEO of MaxCyte. “Medinet is a clear leader in cell-based therapies in Japan with world-class expertise in immunotherapeutics, and we look forward to a long and very productive relationship.”

## **About Medinet**

Medinet is a leading company in immunotherapy, providing the Immuno-Cell Therapy Total Support Services for cancer treatment with medical institutions and clinics in Japan. Immuno-cell therapy is an advanced medical technology utilizing a patient's own immune cells, which are cultured and processed to enhance their activity, and then re-administered to the patient to prime the immune system to combat tumor or viral infected cells. The Immuno-Cell Total Support Service is a tailor-made medical service which provides comprehensive immuno-cell therapy including technology and know how, skilled staff, equipment and facilities, and special materials and reagents in cell processing, as well as an information system to monitor the total procedure. Medinet is also involved in several Immuno-Cell Therapy clinical studies with university hospitals and medical institutions domestically and internationally, strengthening efficacy of immunotherapy and establishing this therapy as a standard for cancer treatment. Based on its leading technology and knowledge from molecular immunology and cellular engineering, Medinet has accumulated extensive clinical understanding in autologous cell processing; serving more than 4,800 patients through contracted clinics since 1999. Medinet went public in October, 2003 on the MOTHERS, Tokyo Stock Exchange.

## **About MaxCyte**

MaxCyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of partnered and internally developed therapeutic candidates. The Company's proprietary *ex vivo* cell loading technology overcomes critical obstacles, such as safety, scalability, and reproducibility, which are fundamental to successful cell-based therapies. MaxCyte has demonstrated the value of its versatile technology by building a pipeline of six partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as developing several drug candidates in collaboration with leading researchers: one in Phase I/II clinical trials for treatment of chronic lymphocytic leukemia (CLL) and several preclinical candidates in oncology and regenerative medicine. More than 14 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at CBER. For more information, visit [www.maxcyte.com](http://www.maxcyte.com).